彭布罗利珠单抗
医学
肺癌
化疗
肿瘤科
免疫疗法
内科学
PD-L1
癌症
作者
R. Descourt,C. Chouaïd,M. Pérol,Benjamin Besse,Laurent Greillier,O. Bylicki,Charles Ricordel,Florian Guisier,Radj Gervais,Roland Schött,J.B. Auliac,G. Robinet,C. Decroisette
出处
期刊:Future Oncology
[Future Medicine]
日期:2021-06-22
卷期号:17 (23): 3007-3016
被引量:9
标识
DOI:10.2217/fon-2020-1202
摘要
Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer without EGFR mutations or ALK rearrangements, regardless of PD-L1 expression status. A study comparing chemotherapy plus pembrolizumab versus pembrolizumab alone has never been performed in patients with PD-L1 ≥50%. The aim of this trial is to perform such a comparison as first-line treatment in patients not eligible for locally advanced treatment who have expression of PD-L1 on ≥50% of tumor cells. The expected results are a reduction in the risk of early progression. A higher objective tumor response is also expected with the combination of chemotherapy and pembrolizumab compared with pembrolizumab alone. The study will allow a direct comparison of the proportion of patients who derive long-term benefit from the treatment. Clinical trial number: EudraCT (2020-002626-86); ClinicalTrials.gov ( NCT04547504 ).
科研通智能强力驱动
Strongly Powered by AbleSci AI